FDA Vows to Act Against Unlawful CBD Products While Protecting Confidential Research

March 10, 2020 09:00:10

The U.S. cannabidiol industry has been chaotic ever since it was birthed after the 2018 Farm Bill. Although the legislation legalized the cultivation and sale of industrial hemp and its extracts, it didn’t say much more. Aside from defining hemp as cannabis with less than 0.3% THC, the Bill didn’t create a comprehensive regulatory framework for hemp extracts like cannabidiol, and that has been a constant thorn in the CBD industry’s side.

In the year since hemp and its extracts became legal, the sector has blossomed, and the market is filled with thousands of products. Already worth millions of dollars in sales, experts predict the CBD industry will hit $20 billion by 2024. According to the U.S. Food and Drug Administration (FDA), the popularity and accessibility of CBD products might fool consumers into thinking…

Read More >>

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.